Background: Preliminary results in small single-center studies after stenting with the GORE TIGRIS Vascular Stent (W. L. Gore & Associates, Flagstaff, Ariz) show promising short-term primary patency rates, but larger, multicenter studies are needed. This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.
Lower extremity peripheral artery disease (PAD) is the third leading cause of atherosclerotic cardiovascular morbidity, followed by coronary artery disease and stroke. 1 Untreated, critical limb ischemia (CLI) portends a grim prognosis, with up to 40% of patients requiring a major amputation (an above-the-knee or below-theknee amputation) #1 year of diagnosis. 2 The efficacy of noninvasive treatment strategies for PAD has been well documented. 3 In the past, the primary approach to stenoses in the femoropopliteal region was primary balloon angioplasty with a standard balloon. However, patency results with this approach alone have been disappointing, with patency rates as low as 26% reported at 2 years in longer femoropopliteal lesions. 4 Subsequently, therapies were developed that combined balloon angioplasty with endovascular stenting that dramatically improved long-term outcomes compared with plain balloon angioplasty. 5 Revascularization of peripheral arteries is particularly challenging because of the anatomic features of the vessels. The femoropopliteal arterial segment is known to be exposed to special mechanical influences. The superficial course of the artery with crossing of flexion points as well as interaction with the surrounding musculature exposes the artery to relevant external forces, including compression, torsion, and elongation. The association of target vessel restenosis with stent fractures has led to a re-examination of the mechanical properties of nitinol stents. 6 Implantation of the next generation of nitinol stents became a widely accepted and recommended technique, resulting in improved clinical outcome. 7, 8 This improvement may be explained by a more advanced stent design with enhanced flexibility. The development of a second-generation laser-cut nitinol stent improved patency rates up to 60% to 80% at 12 months. [9] [10] [11] Nevertheless, there is a considerable risk of stent fractures after femoropopliteal stenting with these second-generation stents, which is associated with a higher in-stent restenosis and reocclusion rate, with incidence rates up to 37%. 6 Rather than laser-cut nitinol tubes, the GORE TIGRIS Vascular Stent (W. L. Gore & Associates, Flagstaff, Ariz), a third-generation dual-component stent system, was developed to address the biomechanical forces in the superficial femoral artery (SFA) and popliteal arteries. Preliminary results showed promising primary patency rates of 91.7% at 6 months and 85.5% at 12 months. 12, 13 However, additional midterm and long-term results are lacking. This retrospective study was conducted to validate the preliminary, single-center results with the GORE TIGRIS Vascular Stent in a larger multicenter study and assess the performance of the device out to 2 years.
METHODS
Study design. A retrospective analysis of all patients treated with the GORE TIGRIS Vascular Stent between July 2012 and December 2015 at three different sites in France was performed. Enrollment was considered for all consecutive patients with symptoms of claudication or CLI with a clinical Rutherford-Becker classification $2. Patients were selected if they had a symptomatic occlusion or >70% stenosis of a SFA or popliteal artery. There were no restrictions on the maximum number of GORE TIGRIS devices.
The Institutional Review Board of each site approved the protocol, data collection tool, and study design, with the understanding that informed consent was not required due to the study's retrospective nature.
Material. The GORE TIGRIS is a flexible, self-expanding endoluminal stent consisting of a single, helically wound nitinol (nickel/titanium) wire with the apices connected by a fluoropolymer lattice. The GORE TIGRIS Stent is coated with the CARMEDA BioActive Surface (CBAS Surface; Carmeda AB, Upplands Väsby, Sweden) consisting of a stable, covalently bonded reducedmolecular-weight heparin of porcine origin, which provides a thromboresistant surface.
The stent is compressed and attached to a triaxial delivery catheter. To facilitate accurate stent placement, two radiopaque metallic bands are attached to the catheter shaft, marking the ends of the compressed stent. The stent system includes a delivery system (6F for 5-to 7-mm-diameter implants and 7F for 8-mm-diameter implants) that consists of a delivery catheter and a handle. After unlocking, the stent position is finalized and deployed by turning a thumb wheel that pulls back an everting sheath. The stents used in this study ranged in diameters from 5 to 8 mm and in lengths from 30 to 100 mm.
Patient cohort. The study cohort comprised 215 patients (239 separate lesions) who underwent a baseline physical and clinical examination with focus on lower limb ischemia. They were categorized according to the Rutherford-Becker classification.
14 A baseline arterial Doppler and duplex ultrasound examination was performed to precisely identify the location, the hemodynamic characterization, and the stenosis grade and length of the lesion. Selective angiography of the femoropopliteal segment was performed to identify the anatomic characteristics and define the lesion. Patients with de novo postangioplasty or postatherectomy stenosis that required additional stenting after angioplasty were included in the data collection. Follow-up data were obtained retrospectively from the patients' records. Clinical evaluation of stent patency was performed at clinical follow-up visits by symptom assessment and duplex ultrasound imaging. Routine follow-up was performed at 1, 3, 6, 12, 18, and 24 months postoperatively.
Procedure and medication. The angiography and the intervention were performed in the operating room under general anesthesia. An ipsilateral antegrade approach was chosen to access the lesion. A 6F or 7F introducer sheath was then introduced and flushed with serum heparin (20 mL).
Heparin (50 U/kg) was given immediately after the puncture and before angioplasty or stent deployment. During the procedure, a 0.035-inch guidewire was used to pass through the lesions. Subintimal angioplasty was performed in cases of chronic total occlusion. Entry transition to the subintimal space and re-entry to the intraluminal space was performed using the 0.035-inch guidewire with support of a 4F guide catheter. Re-entry problems occurred in two cases, at which time a switch to a retrograde approach was necessary.
Predilatation of the lesion was at the discretion of the interventionalist and was performed using conventional techniques. Predilation was at nominal pressure to match the vessel diameter at a minimum level. After the lesion was assessed and predilated, a self-expandable GORE TIGRIS Vascular Stent was implanted to cover the entire lesion. In case of lesion lengths >20 cm, double stenting was used with an overlap of at least 1 cm or in end-toend placement. For patients treated for lesions longer than 20 cm, we used two maximum stents. Angioplasty areas with good iconographic and hemodynamic results were not stented. Recommendation: The authors suggest that using a nitinol polytetrafluroethylene-coated heparin-bonded stent in the superficial femoral and popliteal arteries gives equal or superior results to existing technologies.
ARTICLE HIGHLIGHTS
Double stenting was performed in 20 of the 98 popliteal lesions and in 10 of the 141 SFA lesions. The stent size was determined according to the instruction for use. Stent sizing and implantation were left to the discretion of the operator based on visual estimation; however, the manufacturer recommends oversizing the implant by 5% to 20%. Sizing for Rutherford 3 patients was performed using preprocedural computed tomography scans. Sizing for other patients was performed using a predilation balloon or pigtail catheter. Postdilatation was performed in every lesion. In case of chronic total occlusion, a subintimal recanalization was performed.
The same antiplatelet regimen was recommended for all patients: aspirin or clopidogrel (or ticlopidine) was started at least 8 days before the intervention in patients with coronary artery disease and clopidogrel alone in patients without coronary artery disease. Dual-antiplatelet therapy was continued for at least 6 months postprocedure.
Outcome measures. The primary outcome of this study was primary patency of the GORE TIGRIS Vascular Stent for the first 2 years after the intervention, defined as a duplex velocity ratio <2.5 at the stented target. Secondary outcome measures included primary patency at 3, 6, 12, and 18 months, primary assisted patency and secondary patency, and procedural success, defined as a completely unfolded stent with a postimplantation residual stenosis <30%.
Statistical evaluation. Continuous data are presented as mean 6 standard deviation, and categoric data are given as percentages (counts/sample). Primary, secondary, and primary assisted patency, were estimated using the Kaplan-Meier method. Statistical analyses were performed using SAS software (SAS Institute Inc, Cary, NC).
RESULTS
During the study period, 215 patients were identified who presented with claudication or CLI and who were treated with the GORE TIGRIS Vascular Stent. The Rutherford-Becker classification was class 2 in 49% of the patients class 3 in 21%, class 4 in 28%, class 5 in 2%, and class 6 in 0.5% (one patient). In this population, 239 lesions were treated. Demographics and lesion characteristics are reported in Table I . Patients (68% men) were a mean age of 74 6 12 years (range, 49-102 years). Of the 239 lesions, 141 (59%) were located in the SFA and 98 in the popliteal artery. The mean lesion length was 86.8 mm (range, 30-360), and reference vessel diameters averaged 5.2 mm (range, 4.3-7.1 mm). Diameter stenosis averaged 85%, and calcification was observed in 82.3%. Chronic total occlusion of the femoropopliteal vessels was present in 22 lesions.
All lesions were successfully treated with the GORE TIGRIS Vascular Stent. All patients with Rutherford class 5 or 6 symptoms presented with significant multifocal lesions. These patients all benefited from simultaneous treatment with angioplasty of lesions below the knee. Two underwent angioplasty of the anterior tibial artery, proximally for one and distally for the other, and three underwent angioplasty of the peroneal artery for multifocal lesions.
Doppler ultrasound data were available in 177, 141, 109, 63, and 49 patients at 3, 6, 12, 18, and 24 months, respectively, to evaluate patency. Five patients presented with restenosis at 3 months. At the follow-up visits at 6, 12, 18, and 24 months, 11, 25, 30, and 32 patients, respectively, presented with significant restenosis.
Seven patients died during the follow-up period: however, none of the deaths were related to the intervention. The 30-day mortality was 1% (two patients) and the overall mortality rate was 3.3%. The survival estimated proportions are 92% at 24 months with a Kaplan-Meier curve (Fig 1) . Of the seven deaths during follow-up, 1 was caused by a pulmonary embolism, 1 occurred after a heart operation, 1 was due to cardiorespiratory failure, 1 because of neoplasia, 1 after bilateral leg amputation, and 2 were of unknown causes. Two diabetic patients required major amputations: one patient underwent a major amputation below the knee and another had a bilateral leg amputation. The second patient died after the amputation. Both patients progressed to amputation as a failure of the intervention to provide limb salvage. Initial lesions were too diffuse to obtain limb salvage. The limb salvage rate was 98.7%. The Kaplan-Meier estimated limb salvage was 97% at 24 months (Fig 2) .
Six patients underwent a minor toe amputation. All major amputations were performed after a negative evolution of trophic disorders despite satisfactory revascularization and local care performing well. In any case, the amputations were not a question of failure of endovascular revascularization. For the six patients with a toe amputation, necrosis was present and unrecoverable before revascularization. We used a drug-eluting balloon or placed a new stent to treat stenotic lesions detected during follow-up. For the treatment of thrombosed GORE TIGRIS stents, we first attempted endovascular lysis, followed by surgical bypass in the event this approach failed.
Overall primary patency was 97% (95% confidence interval [CI], 94%-99%) after 3 months, 93% (95% CI, 88%-96%) after 6 months, 82% (95% CI, 74%-87%) after 12 months, and 67% (95% CI, 54%-77%) after 24 months (Fig 3) .
Primary patency for the SFA lesions was 100% at 3 months, 98% (95% CI, 91%-99%) at 6 months, 84% (95% CI, 73%-90%) at 12 months, and 74% (95% CI, 59%-83%) at 24 months (Fig 4, A) . Primary patency for the popliteal artery lesions was 94% (95% CI, 86%-97%) at 3 months, 87% (95% CI, 77%-93%) at 6 months, 79% (95% CI, 67%-88%) at 12 months, and 74% (95% CI, 56%-85%) at 18 months (Fig 4, B) .
Overall primary assisted patency rates were 97% (95% CI, 93%-99%) at 6 months, 95% (95% CI, 90%-97%) at 1 year, and 85% (95% CI, 71%-92%) at 2 years (Fig 5) . Secondary patency was 100% until 6 months and dropped less than 1%, to 99%, at the end of the analysis at 24 months (Table II) .
DISCUSSION
This retrospective study evaluated the performance of the GORE TIGRIS Vascular Stent for femoropopliteal artery disease in large, multicenter study and assessed the performance of the device out to 2 years. The previously published preliminary results at 6 and 12 months document the benefits of this dual-component stent for the treatment of the SFA and popliteal arteries. Piorkowski et al 12, 13 reported a primary patency rate of 91.7% at 6 months and 85.5% at 12 months assessed in 32 patients. Our data demonstrate similar findings of a very good performance, with primary patency rates of 93.2% at 6 months and 81.5% at 12 months. Longer, more calcified lesions and more significant popliteal artery disease in our study likely explain our slightly lower patency rates compared with Piorkowski et al. 12, 13 Similarly, the secondary patency rate of 99.1% at 24 months is very encouraging and compares favorably with the reported literature from novel interwoven nitinol stents. 15, 16 Based on our extensive experience implanting the GORE TIGRIS Vascular Stent, we believe the best results are achieved by the following recommendations: Predilation should be performed with the same size balloon as the reference vessel using an inflation time of 3 minutes. The pressure should be gradually increased until a satisfactory full deployment of the balloon is visible under angiography. In most cases these are pressures of 6 to 8 atmospheres. After 3 minutes, the balloon should be deflated slowly. The implanted stent should then be sized to the same as the diameter of the balloon. Postdilation was performed in every lesion to obtain an optimal stent deployment.
Vascular devices should demonstrate a behavior as close as possible to the mechanical properties of human arteries, such as compliance, long-term durability, and in biological properties such as biocompatibility, luminal surface healing, and thrombogenicity. 17 As a result of its anatomic features, the femoropopliteal arterial segment is known to be exposed to special mechanical influences. The GORE TIGRIS Vascular Stent was specifically developed for this challenging environment. It has a unique combination of a single helically wound nitinol wire frame and an expanded polytetrafluoroethylene interconnecting structure, which provides flexibility and significantly reduces metal stress when the device is bent. This flexibility allows it to naturally conform to the different movements of the SFA and popliteal artery. As a result of the lack of longitudinal connections, stent stiffening in the artery is virtually eliminated. Preclinical testing has shown its superiority compared with laser-cut and woven nitinol stent designs in deformations, compression, and elongation. 18 In our opinion, the GORE TIGRIS Vascular stent has the precision of placement that is typically only seen with balloon-expandable stents, whereas the highly flexible GORE TIGRIS Vascular Stent had more than sufficient radial strength to treat even the most stenotic lesions in this study. All devices were easily placed at the intended site and implanted with a residual stenosis of <30% resulting in a procedural success of 100% despite a high prevalence of calcification (82.3% of all lesions). No complications were reported 30 days after treatment. In our patients, no obvious cases of stent fractures were detected. However, because we did not perform an extensive X-ray screening for stent fractures, no conclusions can be drawn concerning stent fractures to date.
The surface of the stent features the CARMEDA BioActive Surface, which is intended to provide a thromboresistant surface. None of our patients showed any clinical indication of thrombus formation after implantation, and no patients were treated for acute thrombus formation. The antithrombogenic features of this coating could partly explain our lack of thrombus observed. Results of this clinical investigation are promising in femoropopliteal artery disease. One of the limitations of this study was the retrospective design. Prospective, randomized trials are needed to further investigate the performance of this device. Although the primary patency was good up to 2 years, further research is necessary to delineate the long-term performance. Clinical outcome measures, such as the ankle-brachial index, Rutherford-Becker classification, or pain-free walking capacity after treatment with the GORE TIGRIS Vascular Stent, have not been investigated so far. Further research might elucidate on those important clinical parameters as well.
CONCLUSIONS
The results of this retrospective study indicate that patients presenting with PAD due to femoropopliteal artery disease and who seem technically suitable for treatment with the GORE TIGRIS Vascular Stent show sustained clinical efficacy beyond the early-term results. Our primary and secondary patency rates of 67% and 99%, respectively, at 24 months represent a promising outlook for the efficacy of GORE TIGRIS Vascular Stents.
Prospective multicenter randomized controlled trials with long-term follow-up are needed to confirm the sustained efficacy of the GORE TIGRIS Vascular Stent. 
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